This is a StreetInsider.com Premium Only Page

(STAB) – Globe Newswire

Mar 15, 2023 08:00 AM Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

Aug 26, 2022 07:49 AM Nasdaq Resumes Trading in Statera Biopharma, Inc.

Aug 25, 2022 11:48 AM Nasdaq Halts Statera Biopharma, Inc.

Jun 14, 2022 07:30 AM Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

Jun 14, 2022 07:30 AM Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

May 23, 2022 04:05 PM Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

May 23, 2022 04:05 PM Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

May 13, 2022 07:30 AM Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

May 13, 2022 07:30 AM Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Apr 27, 2022 04:10 PM Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

Apr 27, 2022 04:10 PM Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

Apr 22, 2022 05:26 PM Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

Apr 22, 2022 05:26 PM Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

Apr 13, 2022 04:05 PM Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

Apr 13, 2022 04:05 PM Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

Mar 31, 2022 04:05 PM Statera Biopharma, Inc. Files Form 12b-25

Mar 31, 2022 04:05 PM Statera Biopharma, Inc. Files Form 12b-25

Mar 28, 2022 07:30 AM Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Mar 28, 2022 07:30 AM Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Mar 24, 2022 05:28 PM Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering

Mar 24, 2022 05:28 PM Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering

Mar 22, 2022 09:29 AM Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

Mar 22, 2022 09:29 AM Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

Mar 22, 2022 07:38 AM CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering

Mar 22, 2022 07:38 AM CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering

Mar 21, 2022 04:50 PM Statera Biopharma Announces Proposed Underwritten Public Offering

Mar 21, 2022 04:50 PM Statera Biopharma Announces Proposed Underwritten Public Offering

Mar 8, 2022 04:15 PM Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021

Mar 8, 2022 04:15 PM Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021

Mar 7, 2022 07:30 AM Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

Mar 7, 2022 07:30 AM Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

Mar 2, 2022 09:08 AM CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Mar 2, 2022 09:08 AM CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Mar 2, 2022 07:30 AM Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Mar 2, 2022 07:30 AM Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Feb 25, 2022 07:32 AM Statera Biopharma Announces Changes to Board of Directors

Feb 25, 2022 07:32 AM Statera Biopharma Announces Changes to Board of Directors

Feb 22, 2022 07:51 AM Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21

Feb 22, 2022 07:51 AM Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21

Feb 15, 2022 09:04 AM Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease

Feb 15, 2022 09:04 AM Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease

Feb 9, 2022 06:10 PM Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering

Feb 9, 2022 06:10 PM Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering

Feb 6, 2022 10:59 PM Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering

Feb 6, 2022 10:59 PM Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering

Dec 29, 2021 07:32 AM Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease

Dec 29, 2021 07:32 AM Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease

Dec 20, 2021 04:03 PM Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Dec 20, 2021 04:03 PM Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Dec 1, 2021 07:32 AM Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod